These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15640656)

  • 1. Activated protein C: beyond 28 days.
    Manocha S; Walley KR
    Crit Care Med; 2004 Nov; 32(11):2348-9. PubMed ID: 15640656
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of drotrecogin alfa depends on severity of illness.
    Deans KJ; Minneci PC; Eichacker PQ; Natanson C
    Crit Care Med; 2004 Nov; 32(11):2347. PubMed ID: 15640655
    [No Abstract]   [Full Text] [Related]  

  • 4. A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.
    Carlet J
    Intensive Care Med; 2004 May; 30(5):994; author reply 995. PubMed ID: 15083270
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating severe sepsis with drotrecogin alfa (activated).
    Wyncoll D
    Hosp Med; 2003 Mar; 64(3):168-72. PubMed ID: 12669484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 8. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 10. What is the role of recombinant activated protein C in the management of sepsis?
    Alvarado J; Castro R
    Medwave; 2016 Dec; 16(Suppl5):e6801. PubMed ID: 28032853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 12. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of sepsis in the critically ill patient: key aspects.
    Vincent JL
    Expert Opin Pharmacother; 2006 Oct; 7(15):2037-45. PubMed ID: 17020431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated protein C (Xigris): a drug in trouble.
    Vangerow B; Mignini MA
    Acta Anaesthesiol Scand; 2007 Feb; 51(2):261-2. PubMed ID: 17261152
    [No Abstract]   [Full Text] [Related]  

  • 15. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 16. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Rustige J
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698; author reply 1699-70. PubMed ID: 15273923
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?
    Mathiak G; Neville LF; Grass G
    Crit Care Med; 2003 Jan; 31(1):310-1. PubMed ID: 12545036
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.
    Carlet J
    Crit Care Med; 2006 Feb; 34(2):525-9. PubMed ID: 16424736
    [No Abstract]   [Full Text] [Related]  

  • 19. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 20. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.